Medical Condition News

RSS

Proactive therapies may prove to avert stroke in patients with atrial fibrillation

One evening last March, Larry Ambrose left his bed in the middle of the night to check the time. Much to the 71-year-old's surprise, he was only able to see three out of the four glowing numbers on the digital clock in his kitchen. Ambrose returned to bed, but within days was hospitalized for what was later diagnosed as a stroke. After extensive testing, his physicians told him they could not determine the cause.

8 Dec 2010

Diabetes has negative impact on women's sex lives

Almost half of women in the US who suffer from Type 1 or 2 diabetes report that it has a negative impact on their sex lives, according to a new study released today by MicroMass Communications, Inc., a leader in behavioral marketing in the healthcare industry. The research, which highlighted the need for improved education and support to help women build confidence in their ability to overcome the challenges of the disease, was conducted with a representative sample of more than 800 women with diabetes.

8 Dec 2010

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

Alexza Pharmaceuticals, Inc. announced today that the Company has scheduled an End-of Review meeting with the U.S. Food and Drug Administration in December to discuss the Complete Response Letter regarding the Company's New Drug Application for AZ-004 (Staccato loxapine).

8 Dec 2010

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine's Sue and Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world's first clinical trial using human neural stem cells to treat spinal cord injury.

8 Dec 2010

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

QLT Inc. today announced that QLT091001, the Company's oral synthetic retinoid, has been granted orphan drug designation for the treatment of Retinitis Pigmentosa (RP) from the U.S. Food and Drug Administration (FDA). This follows the FDA grant of orphan drug designation for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA) also on December 7, 2010.

8 Dec 2010

NIH awards Scripps Research $2.35M to study new treatment for obesity

The Scripps Research Institute has been awarded a $2.35 million grant from the National Institutes of Health to study a new way of treating obesity as part of a national consortium with the Dana-Farber Cancer Institute.

8 Dec 2010

One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

One Lambda Inc., a leading manufacturer and supplier of quality products and technology for the HLA transplant community, and Luminex Corporation have agreed to a long-term renewal of their 10-year strategic partnership aimed at developing platforms and technologies for human leukocyte antigen (HLA).

From Luminex 8 Dec 2010

New sensitive blood test could determine unrecognized heart disease

A more sensitive version of a blood test typically used to confirm that someone is having a heart attack could indicate whether a seemingly healthy, middle-aged person has unrecognized heart disease and an increased risk of dying, UT Southwestern Medical Center researchers have found.

7 Dec 2010

Psychotic depression: the reason for treatment failure with antidepressants

A new study shows that patients with depression who also have psychotic-like symptoms, feelings of being persecuted, or believing others are plotting against them or hearing voices are less likely to respond to antidepressants. The study also showed that bipolar disorder does not appear to be associated with treatment resistance in patients with depression as believed earlier.

7 Dec 2010

Cognitively-impaired human research subjects need better protection

Practices for protecting human research subjects with Alzheimer’s disease and other conditions that make them incapable of giving informed consent are widely variable and in need of more concrete ethical and legal guidance, according to a study in IRB: Ethics & Human Research.

7 Dec 2010

Sheathless transradial intervention highly successful in treating complex lesions

Cardiologists from the Mayo Clinic performed sheathless transradial percutaneous coronary intervention (PCI) to remedy complex lesions, achieving a 90% success rate with no radial complications. Standard guiding catheters were used during the procedure. Details of this novel approach—overcoming the last hurdle to greater adoption of transradial PCI in the U.S.—are published in the December issue of Catheterization and Cardiovascular Intervention, the official journal of The Society for Cardiovascular Angiography and Interventions.

7 Dec 2010

European summit agrees that lifestyle change is the only answer to heart disease

‘Some progress, but the big challenges remain’. This was the verdict after the European Society of Cardiology (ESC) hosted the 2010 European Summit on CVD Prevention on 30 November. The summit was attended by a broad cross-section of medical experts, healthcare organisations, national societies, regulators and representatives from the European Union (EU).

7 Dec 2010

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.

7 Dec 2010

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Abbott and Bristol-Myers Squibb Company today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.

7 Dec 2010

$Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL$

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of ALCL. The data were presented today during an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

7 Dec 2010

Mental Health Research Network receives grant to create data resource for mental health researchers

Ask anyone: There must be better ways to treat mental health problems. Treatment hinges on research. But traditional research is slow-and so expensive that it can't even ask many pressing questions in mental health. And findings from academic settings may not apply to patients or clinicians in the real world of health care.

7 Dec 2010

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

7 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

Medical Condition News

Proactive therapies may prove to avert stroke in patients with atrial fibrillation

Diabetes has negative impact on women's sex lives

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

Researchers synthesize wound-healing peptides

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

FDA grants QLT's QLT091001 orphan drug designation for treatment of Retinitis Pigmentosa

NIH awards Scripps Research $2.35M to study new treatment for obesity

One Lambda, Luminex renew 10-year human leukocyte antigen technology development partnership

New sensitive blood test could determine unrecognized heart disease

Psychotic depression: the reason for treatment failure with antidepressants

Cognitively-impaired human research subjects need better protection

Sheathless transradial intervention highly successful in treating complex lesions

European summit agrees that lifestyle change is the only answer to heart disease

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Mental Health Research Network receives grant to create data resource for mental health researchers

Cardiologists achieve 90% success rate in sheathless transradial PCI to remedy complex lesions

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News